Salute e Benessere

Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7…

- Preclinical data reveal potential applications in hemolytic anemias and obesity-induced inflammatory anemia - - Preclinical data reveal potential applications in hemolytic anemias and obesity-induced inflammatory anemia - LEHI, Utah , Nov. 10, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced six poster presentations and one oral presentation at the 67 thAmerican Society of...
PR Newswire
10/11/2025

Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation…

The addition of this role represents an important step in CEO Kenneth Bilenberg's strategy to position Avid for continued expansion – and to be the easiest external partner to work with: reliable, predictable, and proactive at every stage. The addition of this role represents an important step in CEOKenneth Bilenberg'sstrategy to position Avid for continued expansion – and to be the easiest external partner to work with: reliable, predictable, and proactive at every stage. "Avid has...
PR Newswire
10/11/2025

Cellex Symposium 2025 Brings Together International Experts to Discuss the…

Driving Innovation and Investment in the Next Era of Immune Cell Therapies Driving Innovation and Investment in the Next Era of Immune Cell Therapies The opening session focused on innovation, funding, and the next generation of immune cell therapy platforms. Dr. Karl Nägler, Sofinnova Partners, provided an insightful overview of venture capital opportunities and challenges in CGT investments, whileKenneth Lockediscussed the use of cell-derived nanoparticles to overcome key barriers...
PR Newswire
10/11/2025

Brainomix Recognized in Global Health Tech Competition for Its Innovative…

"We're honored to be recognized by the American Heart Association for our Brainomix 360 Stroke technology," said Michalis Papadakis, Ph.D., Chief Executive Officer and Co-Founder of Brainomix. "This award affirms our commitment to transforming cardiovascular and stroke care through innovation and scientific rigor." "We're honored to be recognized by the American Heart Association for our Brainomix 360 Stroke technology," saidMichalis Papadakis, Ph.D., Chief…
PR Newswire
10/11/2025

Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through…

/Cas9 license agreement. This agreement grants Dyadic access to ERS’ CRISPR/Cas9 patent portfolio, enhancing Dyadic’s ability to accelerate strain engineering and pathway optimization to enhance productivity, product quality, and innovation across its proprietary bioproduction platforms.“Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s proprietary...
Nasdaq GlobeNewswire
10/11/2025

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior…

Media ReleaseCOPENHAGEN, Denmark; November 10, 2025Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, subject to market and other conditions, $1.5 billion of senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”).Genmab also launched the syndication of a new $2...
Nasdaq GlobeNewswire
10/11/2025

Zenos Health Summit 2025 Concludes Transformative Three-Day Gathering of Global…

The gathering underscores Saudi Arabia's emergence as a global hub for health innovation and longevity science, attracting leading experts and practitioners from around the world. Attendee feedback was overwhelmingly positive, with 80% reporting the summit exceeded expectations and 90% expressing intent to return in 2026 The gathering underscoresSaudi Arabia'semergence as a global hub for health innovation and longevity science, attracting leading experts and practitioners from around the…
PR Newswire
10/11/2025

uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate…

~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 months and supportive trends across key clinical and biomarker endpoints ~~ Preliminary feedback from FDA at a recent pre-Biologics License Application (BLA) meeting for AMT-130 indicated a key shift from prior regulatory communications; uniQure plans to urgently interact with...
Nasdaq GlobeNewswire
10/11/2025

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial…

Atopic dermatitis is a chronic, recurrent, inflammatory skin disease characterized by symptoms such as dry skin, intense itching, and erythema, which significantly impact patients' quality of life. As a high medical need for the treatment of moderate to severe AD remains, there are opportunities to further optimise treatment options and technologies. Atopic dermatitis is a chronic, recurrent, inflammatory skin disease characterized by symptoms such as dry skin, intense itching, and erythema,...
PR Newswire
10/11/2025

A milestone moment for Interlinked - first major distribution agreement signed…

"This is a pivotal moment for Interlinked. Securing a guaranteed revenue of this size at such an early stage of commercialisation is a clear validation of both the demand and the impact of our solution. Now we accelerate," says Katarina Hedbeck, CEO and co-founder of Interlinked AB. " This is a pivotal moment for Interlinked. Securing a guaranteed revenue of this size at such an early stage of commercialisation is a clear validation of both the demand and the impact of our…
PR Newswire
10/11/2025

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market…

REYKJAVIK, ICELAND (November 10, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron’s and Bayer’s injunction...
Nasdaq GlobeNewswire
10/11/2025

Trillion-Dollar Digital Healthcare Transformations Shaped by AI, Quantum and…

From13-17 October 2025, the 45th edition of the world's largest tech and AI show united 6,800 exhibitors, 2,000 startups, and delegations from 180 nations, with digital health and biotech emerging as some of the most dynamic narratives of the week. From genome editing to neurotech and quantum medicine,GITEX GLOBALbecame the platform where the world's brightest minds explored how technology is fundamentally rewriting the science of life. AI's Healthcare Rise: From Genetic Code...
PR Newswire
10/11/2025

Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T…

To date, treatment with LEU011 has been generally well tolerated. In addition, disease control (based on RECIST criteria) has been observed in multiple patients treated with the lowest dose of LEU011. Dose-escalation in the AERIAL trial continues as planned, with additional data from the trial anticipated during the first half of 2026. To date, treatment withLEU011has been generally well tolerated. In addition, disease control (based on RECIST criteria) has been observed in multiple...
PR Newswire
10/11/2025

Camurus reports positive topline results for CAM2056, semaglutide monthly depot

CAM2056 is a monthly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist formulated with Camurus' proprietary FluidCrystal® technology. CAM2056 is a monthly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist formulated with Camurus' proprietary FluidCrystal® technology. Topline results from the Phase1bstudy include: FluidCrystal® is a registered trademark of Camurus. Wegovy® is a registered trademark of Novo Nordisk. For more...
PR Newswire
10/11/2025

Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial…

"The submission of the protocol marks a major milestone and underscores the focus, commitment and outstanding collaboration across our team and global CRO," said Rahul Agrawal, CMO and Head of R&D of Cereno Scientific. "This protocol has been developed in alignment with the FDA's feedback from our recent Type C meeting, and we now look forward to the agency's review ahead of initiating the trial." "The submission of the protocol marks a major milestone and…
PR Newswire
10/11/2025

GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based…

EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel approach to regenerative therapies Pending successfulin vivoproof-of-concept results, GENFIT has an exclusive option to take a license to drive EViv into clinical development Under this research collaboration, EVerZom will contribute exosome expertise with associated bioproduction platform, while GENFIT will spearhead preclinical evaluation of...
Nasdaq GlobeNewswire
10/11/2025

GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment…

Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease modelsSafety data from Phase 1 on healthy volunteers and initial efficacy signals fromex-vivofunctional assays expected by year-end 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025-GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and...
Nasdaq GlobeNewswire
10/11/2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows…

The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomideIn a pivotal PPMS study (FENtrepid), fenebrutinib slowed disability progression at least as effectively as OCREVUS, the only approved therapy in PPMSFull data from both studies will be shared at upcoming medical meetings; once the second RMS study (FENhance 1) has read out, which is expected in the first half of 2026,...
Nasdaq GlobeNewswire
10/11/2025

Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting…

Elevated ApoC3 drives triglyceride-rich lipoprotein accumulation, increasing risks of acute pancreatitis and cardiovascular disease, particularly in diabetes. Current therapies often fail to achieve sustained control in severe cases. RN0361's profound, six-month efficacy from a single dose may address this unmet need and marks a significant advance in lipid management. Elevated ApoC3 drives triglyceride-rich lipoprotein accumulation, increasing risks of acute pancreatitis and cardiovascular...
PR Newswire
10/11/2025

ICP DAS-BMP Attends MOU Signing Ceremony to Mark a New Milestone in…

Their combined expertise spans a wide range of sectors, covering medical-grade TPU material manufacturing, smart manufacturing and IIoT applications, precision extrusion machinery and processing technologies, dehumidifying and drying equipment, injection molding and accessory production, catheter manufacturing and OEM molding services, as well as medical device design and regulatory consulting. Their combined expertise spans a wide range of sectors, covering medical-grade TPU material...
PR Newswire
10/11/2025

Zinzino AB (publ.): Zinzino acquires Mexican company Sanki to increase…

Sanki is a direct sales company in the health segment, operating in North America (USA and Mexico) and South America (Colombia and Peru). Its brand portfolio offers a range of innovative and patented products in the field of health and well-being. The business has a total annual turnover of approximately USD 12 million. The collaboration with Zinzino is expected to add growth through the synergies that arise in the joint networks, combined with the integration of Sanki's product portfolio into…
PR Newswire
08/11/2025

Clinically meaningful pivotal study results for olezarsen in sHTG presented as a…

In CORE and CORE2 43% of patients had extremely high levels of triglycerides ≥880 mg/dL, which is often equated to multifactorial chylomicronemia syndrome (MCS) due to the associated increased accumulation of chylomicrons. The effect on triglyceride-lowering and reduction in acute pancreatitis in the MCS subgroup were in line with the overall population. In CORE and CORE2 43% of patients had extremely high levels of triglycerides ≥880 mg/dL, which is often equated to multifactorial...
PR Newswire
08/11/2025

inne Debuts at CIIE with Global Launch of Two New Products

Promoting Standardized Development of Nutritional Products Promoting Standardized Development of Nutritional Products Addressing prevalent issues in the global children's nutrition market concerning ingredient standards, absorption efficiency, and safety regulations, inne® officially released the "Children's Calcium Quality Standard" in collaboration withChina'sleading enterprise JD Health. This standard defines core indicators such as "Calcium Source Safety," "Dosage…
PR Newswire
08/11/2025

Novo Nordisk will not increase its proposal to acquire Metsera, Inc. 

Bagsværd, Denmark, 8 November 2025– Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera. On 30 October 2025, Novo Nordisk announced the submission of an unsolicited proposal to acquire Metsera, Inc. (Metsera) which was declared superior by Metsera’s board of directors. On 4 November 2025, Novo Nordisk confirmed that it had submitted an updated unsolicited proposal to acquire Metsera price of 62.20 USD per share in cash (equal to an...
Nasdaq GlobeNewswire
08/11/2025
Altri  Comunicati